NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading MRNA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve up to 10% revenue growth in 2026: metric not reported.
View ThesisRevenue is contracting — down about 30% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 34% in its worst 12-month stretch.
View RiskMRNA's growth depends on its expanding mRNA platform and product pipeline. Revenue grew 2% year over year, and the latest earnings report was inline with estimates. It trades at 10× price-to-sales, compared to an 8.7× peer median, suggesting it looks expensive. A specific risk is the 42% chance of missing earnings estimates again. Peer multiples imply a price about 5% below where it trades; this read is provisional.
Trailing returns as of 2026-07-31. MRNA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 25 analysts currently covering MRNA (as of Jul 2026).
Based on 6 Wall Street analysts offering 12-month price targets for MRNA in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Maintain strong cash position
Lowering cash cost guidance improves cash position outlook.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $54.82
The last 12 months of price, then the range of analyst 12-month targets from today’s $54.82.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Norovirus vaccine issues could hinder revenue growth.
Advances: Target up to 10% revenue growth in 2026
Narrowing losses indicate progress towards revenue growth target.
Norovirus shot failure impacts growth objectives.
New competition may hinder revenue growth objectives.
First patient in trial supports growth objectives.
Legal issues could impact revenue growth and operational focus.
Potential drug approvals align with revenue growth objectives.
